The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

Steven P Tanis; Joseph W Strohbach; Timothy T Parker; Malcom W Moon; Suvit Thaisrivongs; William R Perrault; Todd A Hopkins; Mary L Knechtel; Nancee L Oien; Janet L Wieber; Kevin J Stephanski; Michael W Wathen

doi:10.1016/j.bmcl.2010.01.094

The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1994-2000. doi: 10.1016/j.bmcl.2010.01.094. Epub 2010 Jan 25.

Authors

Steven P Tanis¹, Joseph W Strohbach, Timothy T Parker, Malcom W Moon, Suvit Thaisrivongs, William R Perrault, Todd A Hopkins, Mary L Knechtel, Nancee L Oien, Janet L Wieber, Kevin J Stephanski, Michael W Wathen

Affiliation

¹ Global Research and Development, Pfizer Inc., San Diego, CA 92121, USA. sptanis@sbcglobal.net

PMID: 20167488
DOI: 10.1016/j.bmcl.2010.01.094

Abstract

Discovery efforts were focused on identifying a non-nucleoside antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA polymerase inhibition and in vitro antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides.

MeSH terms

Antiviral Agents / chemistry*
Antiviral Agents / pharmacology
Drug Design
Protease Inhibitors / chemistry*
Protease Inhibitors / pharmacology
Quinoxalines / chemistry*
Quinoxalines / pharmacology
Serine Endopeptidases / drug effects*

Substances

Antiviral Agents
Protease Inhibitors
Quinoxalines
Serine Endopeptidases
assemblin